Insulet Company Profile (NASDAQ:PODD)

About Insulet

Insulet logoInsulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The OmniPod System consists of the OmniPod, a small, self-adhesive disposable tubeless OmniPod device, which is worn on the body for approximately three days at a time and its wireless handheld Personal Diabetes Manager (PDM). The Company purchases OmniPods pursuant to its agreement with Flextronics. It also partners with pharmaceutical and biotechnology companies to tailor the OmniPod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. It sells the OmniPod System and other diabetes management supplies in the United States through direct sales to customers or through its distribution partners. The Company purchases OmniPods pursuant to its agreement with Flextronics. The OmniPod System is available in Europe, Canada and Israel.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Equipment
  • Exchange: NASDAQ
  • Symbol: PODD
  • CUSIP: 45784P10
Key Metrics:
  • Previous Close: $45.96
  • 50 Day Moving Average: $42.47
  • 200 Day Moving Average: $40.10
  • 52-Week Range: $26.50 - $46.92
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -287.25
  • P/E Growth: -4.92
  • Market Cap: $2.64B
  • Outstanding Shares: 57,426,000
  • Beta: 1.42
  • Net Margins: -12.95%
  • Return on Equity: -87.46%
  • Return on Assets: -10.74%
  • Debt-to-Equity Ratio: 5.05%
  • Current Ratio: 6.67%
  • Quick Ratio: 6.07%
Additional Links:
Companies Related to Insulet:

Analyst Ratings

Consensus Ratings for Insulet (NASDAQ:PODD) (?)
Ratings Breakdown: 4 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.69)
Consensus Price Target: $43.27 (5.85% downside)

Analysts' Ratings History for Insulet (NASDAQ:PODD)
DateFirmActionRatingPrice TargetDetails
2/13/2017Canaccord GenuityReiterated RatingHold$39.00View Rating Details
1/8/2017BTIG ResearchReiterated RatingBuy$42.00View Rating Details
1/6/2017Robert W. BairdUpgradeNeutral -> Outperform$39.00 -> $47.00View Rating Details
11/17/2016J P Morgan Chase & CoReiterated RatingHold$38.00View Rating Details
11/17/2016WedbushReiterated RatingOutperform$48.00View Rating Details
11/9/2016B. RileyReiterated RatingNeutral$40.00View Rating Details
11/7/2016Leerink SwannReiterated RatingOutperform$55.00 -> $50.00View Rating Details
8/16/2016Piper Jaffray CompaniesReiterated RatingOverweight$52.00View Rating Details
8/4/2016Jefferies Group LLCBoost Price TargetBuy$41.00 -> $45.00View Rating Details
5/16/2016Sterne Agee CRTReiterated RatingNeutralView Rating Details
4/29/2016William BlairUpgradeMarket Perform -> OutperformView Rating Details
2/26/2016Feltl & Co.UpgradeHold -> Buy$35.00View Rating Details
2/26/2016Benchmark Co.UpgradeHold -> Buy$30.00 -> $40.00View Rating Details
1/7/2016Cowen and CompanyBoost Price Target$40.00View Rating Details
12/3/2015Northland SecuritiesReiterated RatingMarket PerformView Rating Details
11/2/2015Morgan StanleyInitiated CoverageEqual -> Equal Weight$32.00View Rating Details
5/1/2015Oppenheimer Holdings, Inc.Lower Price TargetMarket Perform$33.00 -> $31.00View Rating Details
(Data available from 2/26/2015 forward)


Earnings History for Insulet (NASDAQ:PODD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017Q416($0.05)$100.61 millionN/AView Earnings Details
11/3/2016Q316($0.09)($0.05)$89.75 million$94.90 millionViewN/AView Earnings Details
8/3/2016Q216($0.17)($0.08)$81.10 million$87.30 millionViewN/AView Earnings Details
4/28/2016Q116($0.19)($0.19)$79.06 million$81.21 millionViewListenView Earnings Details
2/25/2016Q415($0.26)($0.48)$91.89 million$100.10 millionViewListenView Earnings Details
11/5/2015Q315($0.26)($0.33)$83.56 million$87.30 millionViewListenView Earnings Details
8/12/2015Q215($0.13)($0.27)$70.32 million$75.60 millionViewListenView Earnings Details
4/30/2015Q115($0.10)($0.21)$68.20 million$61.20 millionViewN/AView Earnings Details
2/26/2015Q414($0.04)($0.10)$73.52 million$72.60 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.06)$72.94 million$72.00 millionViewN/AView Earnings Details
5/7/2014Q114($0.06)($0.11)$68.47 million$69.20 millionViewN/AView Earnings Details
2/27/2014Q413($0.09)($0.04)$67.94 million$68.53 millionViewN/AView Earnings Details
11/7/2013Q313($0.16)($0.39)$62.01 million$61.10 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.19)($0.20)$60.47 million$60.09 millionViewN/AView Earnings Details
5/6/2013Q1 2013($0.21)($0.20)$57.26 million$57.40 millionViewN/AView Earnings Details
2/27/2013Q4 2012($0.21)($0.21)$59.12 million$57.80 millionViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.26)$54.93 million$54.80 millionViewN/AView Earnings Details
8/8/2012($0.25)($0.30)ViewN/AView Earnings Details
5/9/2012($0.28)($0.31)ViewN/AView Earnings Details
2/9/2012($0.26)($0.30)ViewN/AView Earnings Details
11/3/2011($0.25)($0.29)ViewN/AView Earnings Details
8/2/2011($0.21)($0.42)ViewN/AView Earnings Details
5/9/2011($0.22)($0.22)ViewN/AView Earnings Details
2/15/2011($0.26)($0.50)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Insulet (NASDAQ:PODD)
Current Year EPS Consensus Estimate: $-0.37 EPS
Next Year EPS Consensus Estimate: $-0.16 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.29)($0.29)($0.29)
Q2 20163($0.21)($0.14)($0.18)
Q3 20167($0.09)($0.04)($0.08)
Q4 20168($0.10)($0.01)($0.06)
Q1 20175($0.12)($0.07)($0.10)
Q2 20175($0.06)($0.03)($0.04)
Q3 20175($0.07)$0.01($0.02)
Q4 20175($0.07)$0.03$0.00
Q1 20181$0.03$0.03$0.03
Q2 20181$0.04$0.04$0.04
Q3 20181$0.09$0.09$0.09
(Data provided by Zacks Investment Research)


Dividend History for Insulet (NASDAQ:PODD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Insulet (NASDAQ:PODD)
Insider Ownership Percentage: 1.90%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/9/2016Charles AlpucheSVPBuy6,600$37.70$248,820.00View SEC Filing  
12/2/2016Patrick J. SullivanCEOBuy40,000$33.89$1,355,600.00View SEC Filing  
12/1/2016Bradley A. ThomasEVPBuy3,100$32.45$100,595.00View SEC Filing  
5/25/2016Regina O SommerDirectorSell8,019$30.42$243,937.98View SEC Filing  
5/18/2016Patrick J SullivanCEOBuy45,000$27.00$1,215,000.00View SEC Filing  
5/13/2016Bradley A ThomasEVPBuy2,975$26.63$79,224.25View SEC Filing  
5/5/2016Bradley A ThomasEVPBuy1,656$30.13$49,895.28View SEC Filing  
3/10/2016Daniel J LevangieInsiderSell12,299$30.89$379,916.11View SEC Filing  
3/7/2016Daniel J LevangieInsiderSell7,663$31.15$238,702.45View SEC Filing  
3/2/2016Jessica HopfieldDirectorBuy3,230$30.91$99,839.30View SEC Filing  
6/5/2015Patrick J SullivanCEOBuy10,000$29.39$293,900.00View SEC Filing  
5/28/2015Patrick J SullivanCEOBuy20,000$27.91$558,200.00View SEC Filing  
5/15/2015Timothy J ScannellDirectorBuy3,500$27.05$94,675.00View SEC Filing  
5/5/2015Bradley A ThomasEVPBuy1,000$27.26$27,260.00View SEC Filing  
5/5/2015Patrick RyanCOOBuy3,669$26.99$99,026.31View SEC Filing  
4/2/2015R Anthony DiehlGeneral CounselSell3,372$30.96$104,397.12View SEC Filing  
3/9/2015Patrick J SullivanCEOBuy10,000$31.93$319,300.00View SEC Filing  
3/2/2015Charles T LiamosDirectorSell4,000$32.00$128,000.00View SEC Filing  
2/12/2015Charles T LiamosDirectorSell4,000$32.00$128,000.00View SEC Filing  
1/2/2015Charles T LiamosDirectorSell4,000$46.08$184,320.00View SEC Filing  
11/3/2014Charles T LiamosDirectorSell4,000$42.95$171,800.00View SEC Filing  
10/1/2014Charles T LiamosDirectorSell4,000$36.58$146,320.00View SEC Filing  
10/1/2014R Anthony DiehlGeneral CounselSell1,250$36.59$45,737.50View SEC Filing  
9/10/2014Charles T LiamosDirectorSell4,000$35.17$140,680.00View SEC Filing  
9/2/2014Duane DesistoCEOSell20,000$36.30$726,000.00View SEC Filing  
8/1/2014Duane DesistoCEOSell20,000$34.23$684,600.00View SEC Filing  
7/1/2014Duane DesistoCEOSell20,000$40.52$810,400.00View SEC Filing  
7/1/2014R Anthony DiehlGeneral CounselSell1,250$39.65$49,562.50View SEC Filing  
6/11/2014R Anthony DiehlGeneral CounselSell17,871$37.09$662,835.39View SEC Filing  
6/9/2014Peter DevlinInsiderSell12,314$37.10$456,849.40View SEC Filing  
4/8/2014Peter DevlinInsiderSell30,000$41.25$1,237,500.00View SEC Filing  
4/3/2014R Anthony DiehlGeneral CounselSell4,617$48.67$224,709.39View SEC Filing  
3/6/2014R Anthony DiehlGeneral CounselSell12,458$49.28$613,930.24View SEC Filing  
3/6/2014Tracey Haas WielinskiVPSell8,275$49.21$407,212.75View SEC Filing  
2/3/2014Charles LiamosDirectorSell11,037$42.93$473,818.41View SEC Filing  
2/3/2014Duane DesistoCEOSell20,000$42.95$859,000.00View SEC Filing  
2/3/2014Peter DevlinInsiderSell30,000$42.82$1,284,600.00View SEC Filing  
1/3/2014Charles LiamosCOOSell86,000$36.02$3,097,720.00View SEC Filing  
1/2/2014Duane DesistoCEOSell20,000$36.07$721,400.00View SEC Filing  
12/3/2013Charles LiamosCOOSell63,808$36.26$2,313,678.08View SEC Filing  
11/18/2013Charles LiamosCOOSell80,000$35.60$2,848,000.00View SEC Filing  
9/3/2013Duane DesistoCEOSell20,000$33.38$667,600.00View SEC Filing  
8/29/2013Sally CrawfordDirectorSell9,000$33.42$300,780.00View SEC Filing  
8/15/2013Regina SommerDirectorSell5,000$33.32$166,600.00View SEC Filing  
8/1/2013Duane DesistoCEOSell20,000$31.85$637,000.00View SEC Filing  
7/1/2013Duane DesistoCEOSell20,000$31.51$630,200.00View SEC Filing  
7/1/2013Peter DevlinInsiderSell30,000$31.48$944,400.00View SEC Filing  
6/14/2013Sally CrawfordDirectorSell31,000$30.47$944,570.00View SEC Filing  
6/10/2013R Anthony DiehlGeneral CounselSell38,455$30.50$1,172,877.50View SEC Filing  
6/3/2013Duane DesistoCEOSell20,000$29.76$595,200.00View SEC Filing  
12/3/2012Brian K RobertsCFOSell10,000$21.92$219,200.00View SEC Filing  
11/1/2012Brian K RobertsCFOSell10,000$21.49$214,900.00View SEC Filing  
9/4/2012Brian K RobertsCFOSell10,000$20.78$207,800.00View SEC Filing  
9/4/2012Duane DesistoCEOSell20,000$20.97$419,400.00View SEC Filing  
9/4/2012Ruthann DepietroVPSell1,000$20.90$20,900.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Insulet (NASDAQ:PODD)
News IconInvestor Update on This Stock: Insulet Corporation (NASDAQ:PODD) - Rives Journal (NASDAQ:PODD) - February 24 at 8:27 AM logoFirst Week of April 21st Options Trading For Insulet (NASDAQ:PODD) - February 23 at 7:23 PM
News IconInsulet’s tubeless closed loop system shows promise (NASDAQ:PODD) - February 20 at 9:25 AM
News IconInsulet touts Omnipod Horizon hybrid closed-loop system in patients with T1D (NASDAQ:PODD) - February 19 at 9:23 AM
News IconInsulet unveils early 'artificial pancreas' feasibility data (NASDAQ:PODD) - February 19 at 9:23 AM logoInsulet Presents Strong Omnipod® Horizon™ Hybrid Closed-Loop Study Results at ATTD in Paris (NASDAQ:PODD) - February 17 at 5:58 PM logo6:01 am Insulet presents 'positive' results from the first feasibility study of the Omnipod Horizon hybrid closed-loop system at the 10th International Conference on Advanced Technologies & Treatments for Diabetes (NASDAQ:PODD) - February 17 at 5:58 PM logoInsulet Completes Acquisition of U.S. Manufacturing Facility in Acton, Massachusetts (NASDAQ:PODD) - February 16 at 6:53 PM logoInsulet Completes Acquisition of U.S. Manufacturing Facility in Acton, Massachusetts (NASDAQ:PODD) - February 16 at 6:53 PM
News IconPeeling Back The Layers on Insulet Corporation (NASDAQ:PODD): Analysts & Street Weigh In - Winfield Review (NASDAQ:PODD) - February 14 at 11:38 PM logoInsulet Corporation to Present at Upcoming Investor Conferences (NASDAQ:PODD) - February 13 at 9:08 AM
News IconInside the Numbers for Insulet Corporation (NASDAQ:PODD) - Baldwin Journal (NASDAQ:PODD) - February 9 at 1:23 AM
News IconInvestor Radar: Focusing in on Shares of Insulet Corporation (NASDAQ:PODD) - The Standard (NASDAQ:PODD) - February 8 at 2:43 AM
News IconFirms & Funds Maintain Significant Positions In Insulet Corporation (NASDAQ:PODD) - Wall Street Beacon (NASDAQ:PODD) - February 1 at 1:54 AM
News IconEquity Rundown: RSI and CCI Check on Insulet Corporation (PODD) - Springdale Times (NASDAQ:PODD) - January 31 at 8:54 PM
News IconAre Insiders Bumping Up Their Positions in Insulet Corporation (NASDAQ:PODD) - Wall Street Beacon (NASDAQ:PODD) - January 31 at 12:58 AM logoMean Rating Of Insulet Corporation (NASDAQ:PODD) At $1.76 (NASDAQ:PODD) - January 30 at 12:45 AM
News IconInvestor Hub: Checking on the Numbers for Insulet Corporation (NASDAQ:PODD) - The Tribune (NASDAQ:PODD) - January 29 at 7:44 PM
News IconStock Focus: Watching RSI Levels on Shares of Insulet Corporation (PODD) - Rives Journal (NASDAQ:PODD) - January 29 at 7:44 PM
News IconAnalysts Peering Into Their Crystal Balls, What's the Sentiment on Insulet Corporation (NASDAQ:PODD) - Wall Street Beacon (NASDAQ:PODD) - January 27 at 1:08 AM
News IconStock Update: Estimates & Target in Focus for Insulet Corporation (NASDAQ:PODD) - Aiken Advocate (NASDAQ:PODD) - January 25 at 1:06 AM
News IconEarnings in Full Force, Analysts Take Aim at Insulet Corporation (NASDAQ:PODD) - Wall Street Beacon (NASDAQ:PODD) - January 25 at 1:06 AM
News IconTrading Review: Technical Survey on Shares of Insulet Corporation (PODD) - Springdale Times (NASDAQ:PODD) - January 25 at 1:06 AM
News IconAnalysts Pounding The Pavement on Insulet Corporation (NASDAQ:PODD): Consensus Update - Wall Street Beacon (NASDAQ:PODD) - January 24 at 12:39 AM logoInsulet Corporation to Announce Fourth Quarter and Full Year 2016 Financial Results on February 27, 2017 (NASDAQ:PODD) - January 23 at 7:38 PM logoInsulet Corporation (NASDAQ:PODD) Mean Rating At $1.76 - (NASDAQ:PODD) - January 22 at 7:03 PM
News IconWall Street and Armchair Analysts Weigh in on Insulet Corporation (NASDAQ:PODD) Heading Into The New Year - Wall Street Beacon (NASDAQ:PODD) - January 17 at 10:59 AM
News IconInsulet Corp PODD Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:PODD) - January 16 at 7:45 PM logoInsulet Corporation (NASDAQ:PODD) Mean Rating At $1.76 (NASDAQ:PODD) - January 15 at 6:50 PM
News IconStock Mounting Higher Mid-Session: Insulet Corporation (NASDAQ:PODD) - Wall Street Beacon (NASDAQ:PODD) - January 14 at 2:16 AM
News IconMarket Focus: Zooming in on Shares of Insulet Corporation (NASDAQ:PODD) - Wall Street Beacon (NASDAQ:PODD) - January 12 at 12:59 AM
News IconInvestor List: Watching Shares of Insulet Corporation (NASDAQ:PODD) - Wall Street Beacon (NASDAQ:PODD) - January 12 at 12:59 AM logo5 Underperformers of 2016: Turnaround Story in 2017? (NASDAQ:PODD) - January 10 at 8:12 PM
News IconCompany Stock Watch: Insulet Corporation (NASDAQ:PODD) - Wall Street Beacon (NASDAQ:PODD) - January 10 at 8:01 AM logoUPDATE: Baird Upgrades Insulet Corporation (PODD) to Outperform (NASDAQ:PODD) - January 6 at 8:02 PM logoAnalyst Upgrades – Insulet Corporation (NASDAQ:PODD) Stock Gets Upgraded By Robert W. Baird from Neutral to Outperform (NASDAQ:PODD) - January 6 at 8:02 PM logoInsulet upgraded by Robert W. Baird (NASDAQ:PODD) - January 6 at 8:02 PM logoInsulet Corporation (NASDAQ:PODD) Records An Impact Score Of 90 - Investor Newswire (NASDAQ:PODD) - January 5 at 1:06 AM logoINSULET CORP Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:PODD) - December 21 at 8:08 PM logoINSULET CORPORATION (NASDAQ:PODD) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:PODD) - December 21 at 9:08 AM logoINSULET CORPORATION (NASDAQ:ILTCL) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:PODD) - December 21 at 12:05 AM logoINSULET CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits (NASDAQ:PODD) - December 20 at 7:03 PM
News IconMarket Scope: F-Score and Volatility Review for Insulet Corporation (NASDAQ:PODD) - The Business Journal (NASDAQ:PODD) - December 20 at 1:54 PM logoInsulet Corporation to Present at Upcoming Investor Conference (NASDAQ:PODD) - December 20 at 1:54 PM
News IconCompany in Focus: Insulet Corporation (NASDAQ:PODD) - Wall Street Beacon (NASDAQ:PODD) - December 19 at 8:35 AM
News IconStock Overview: Moving Average Check on Insulet Corporation (PODD) - Yankee Analysts (NASDAQ:PODD) - December 18 at 7:37 PM
News IconEnterprise Value Review for Insulet Corporation (NASDAQ:PODD) - OIB News (NASDAQ:PODD) - December 18 at 7:24 AM logoETFs with exposure to Insulet Corp. : December 16, 2016 (NASDAQ:PODD) - December 16 at 8:04 PM
News IconFree Cash Flow Score in Focus for Insulet Corporation (NASDAQ:PODD) - Marion Business Daily (NASDAQ:PODD) - December 14 at 8:28 AM logoInsulet Corp. – Value Analysis (NASDAQ:PODD) : December 12, 2016 (NASDAQ:PODD) - December 12 at 7:26 PM


What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Where is Insulet's stock going? Where will Insulet's stock price be in 2017?

13 analysts have issued twelve-month target prices for Insulet's stock. Their forecasts range from $35.00 to $52.00. On average, they anticipate Insulet's share price to reach $43.27 in the next twelve months.

When will Insulet announce their earnings?

Insulet is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

Who owns Insulet stock?

Insulet's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Frontier Capital Management Co. LLC (2.74%), State Street Corp (1.86%), FIL Ltd (1.72%), Arrowpoint Asset Management LLC (1.69%) and Champlain Investment Partners LLC (1.67%). Company insiders that own Insulet stock include Bradley A Thomas, Charles Alpuche, Charles T Liamos, Daniel J Levangie, Jessica Hopfield, Patrick J Sullivan, Patrick Ryan, R Anthony Diehl, Regina O Sommer and Timothy J Scannell.

Who sold Insulet stock? Who is selling Insulet stock?

Insulet's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Frontier Capital Management Co. LLC, Two Sigma Investments LP, Loomis Sayles & Co. L P, Fiera Capital Corp, Franklin Resources Inc., Janus Capital Management LLC and First Republic Investment Management Inc.. Company insiders that have sold Insulet stock in the last year include Daniel J Levangie and Regina O Sommer.

Who bought Insulet stock? Who is buying Insulet stock?

Insulet's stock was acquired by a variety of institutional investors in the last quarter, including FIL Ltd, Arrowpoint Asset Management LLC, Champlain Investment Partners LLC, Allianz Asset Management AG, State Street Corp, Employees Retirement System of Texas, FMR LLC and Menta Capital LLC. Company insiders that have bought Insulet stock in the last two years include Bradley A Thomas, Charles Alpuche, Jessica Hopfield, Patrick J Sullivan, Patrick Ryan and Timothy J Scannell.

How do I buy Insulet stock?

Shares of Insulet can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Insulet stock cost?

One share of Insulet stock can currently be purchased for approximately $45.96.

Insulet (NASDAQ:PODD) Chart for Sunday, February, 26, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Earnings History Chart

Earnings by Quarter for Insulet (NASDAQ:PODD)

Dividend History Chart

Dividend Payments by Quarter for Insulet (NASDAQ:PODD)

Last Updated on 2/26/2017 by Staff